Skip to main content

CH-FIT trial

Interested in our Congenital Heart Fitness Intervention Trial?

Find out more

This pilot study will seek to find biomarkers for blood clot risks in patients who have been given the AstraZeneca COVID-19 vaccine. Patients will be screened 10 days after their first injection to determine their risk of developing a rare blood clot from the vaccine. This study will help increase understanding of why some people are more susceptible to blood clotting, which could allow them to take a preventative treatment to protect them from blood clots.

Interested in our Congenital Heart…

Find out more